Last reviewed · How we verify

NCT05215223: WBV

Effect of Whole Body Vibration on Insulin Resistance in Females With Polycystic Ovarian Syndrome

Completed NA Last updated 17 October 2023
What this trial tests

NA trial testing whole body vibration in Polycystic Ovarian Syndrome in 46 participants. Completed in 10 October 2023.

Timeline
30 March 2022
Primary endpoint
1 October 2023
10 October 2023

Quick facts

Lead sponsorCairo University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment46
Start date30 March 2022
Primary completion1 October 2023
Estimated completion10 October 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 20 to 35, female only, with Polycystic Ovarian Syndrome or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effect of whole body vibration on insulin resistance in females with polycystic ovarian syndrome

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of whole body vibration

Trials testing the same drug.

Other recruiting trials for Polycystic Ovarian Syndrome

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05215223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing